Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11297785 | 0.95 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL520107 | 0.95 | SIRT6 (0.61) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL12312127 | 0.95 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL1784262 | 0.94 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL5410268 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL12312156 | 0.91 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL11299599 | 0.91 | PKM (0.52) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL29833145 | 0.91 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL16982450 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL16982336 | 0.90 | ALDH1A1 (0.50) | ALDH1A1KDM4ELMNAMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795607-B2 | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3202403-A1 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2945636-B1 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160324861-A1 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICAL LLC (US) | 2016-11-10 | — | — | US | disclosed |
| US-9428509-B2 | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9346812-B2 | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2945636-A2 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113429-A2 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324861-A1 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BRCA1, DPYD, TYMP | ALDH1A1 647/4885KDM4E 668/4885LMNA 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.